1. Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
2. Summary This single-center trial compared relapse in women up to 75 years of age with operable nodepositive breast cancer who were randomized to either CMF (cyclophosphamide 100 mg/m2/d d1-14; methotrexate 40 mg/m2i.v. d1,8; 5-fluorouracil (5-Fu) 600 mg/m2i.v. d1,8 q28d for 12 cycles) or observation following surgery. Stratification was according to age ( 49 vs.50-75), number of positive nodes (1-3 vs. 3), and type of mastectomy (radical vs. extended radical), and 5 of 391 enrolled patients were not evaluable. With a follow-up of 27 months, the relapse rate for CMFtreated patients (n 207) was 5.3%, while for control patients (n 179) it was 24%, representing a highly significant difference, p 106. The improvement in relapse-free survival observed with CMF was evident in all stratification groups, as well as pre- and postmenopausal women, and tumor Tmstages 1-3. Nausea during cyclophosphamide treatment was experienced in the majority of patients, and mucositis, alopecia, cystitis, and amenorrhea occurred in 18%, 55%, 28%, and 54%, respectively. Hematologic toxicity was modest, with grade 2 leucopenia and thrombocytopenia (both of which required treatment delay according to the protocol rules) occurring in 4% and 14%, respectively; only 10 patients (4.8%) received 6 cycles.Theaverage dose intensities of the three drugs were cyclophosphamide 76%, methotrexate 80%, and 5-FU 81%.
3. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.
4. A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative Tumors